A clinical trial at Zhongda Hospital in China is testing a combination of fasudil hydrochloride, a Rho-associated kinase (ROCK) inhibitor, with PD-1 immune checkpoint blockade in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). This Phase II open-label trial enrolls patients aged 18 to 85 years who have progressed after at least one docetaxel-containing chemotherapy […]
A phase 1/2 clinical trial investigating valemetostat (DS-3201b), a dual EZH1/2 inhibitor, combined with darolutamide in metastatic castration-resistant prostate cancer (mCRPC) is going to start to recruit participants. This study aims to evaluate the safety, tolerability, and preliminary efficacy of the combination in men whose disease has progressed despite prior androgen receptor pathway inhibitors (ARPIs). […]
A pivotal clinical trial is underway to evaluate the safety and efficacy of combining Lutetium (177Lu) DGUL radioligand therapy with pembrolizumab (Keytruda) for treating metastatic castration-resistant prostate cancer in patients who have progressed after androgen receptor-targeted therapies but have not yet received chemotherapy. The study enrolls men with prostate-specific membrane antigen (PSMA)-positive tumors, with disease […]
GTB-5550, a novel tri-specific natural killer (NK) cell engager drug designed to target the B7-H3 antigen has shown notable promise in advancing cancer immunotherapy for solid tumors, particularly prostate cancer and head and neck squamous cell carcinoma (HNSCC). This drug functions by simultaneously binding to CD16 on NK cells, engaging B7-H3 expressed on tumor cells, […]
A pivotal new Chinese phase 3 clinical trial is poised to begin recruiting patients with metastatic hormone-sensitive prostate cancer to compare two leading androgen receptor antagonists head-to-head: rezvilutamide (SHR3680) versus enzalutamide in mHSPC. This trial represents an important milestone in prostate cancer therapeutics by directly evaluating the efficacy and safety of these oral treatments in […]
This Phase II study investigates the efficacy and safety of three investigational agents: SHR3680 (rezvilutamide), HS-20093, and SHR2554, aiming to enhance outcomes in metastatic prostate cancer through dual-pathway inhibition. SHR3680, a selective androgen receptor (AR) antagonist, represents the latest generation of hormonal therapy designed to inhibit the AR signaling axis, a critical driver of prostate […]
Australian Human Research Ethics Committee has approved the initiation of a first‑in‑human Phase 1 therapeutic trial of RAD 402, a KLK3 (PSA)‑targeting monoclonal antibody labeled with terbium‑161 for patients with metastatic or locally advanced prostate cancer. The approval positions the program to begin site activation and enrollment in Australia, marking a notable milestone for a […]
Phase II EVOLUTION is a randomized study testing whether adding ipilimumab and nivolumab to 177Lu‑PSMA‑617 improves outcomes versus 177Lu‑PSMA‑617 alone in men with metastatic castration‑resistant prostate cancer (mCRPC). Early data presented in 2025 indicate that at 12 months, 33% of patients on the combination were free of progression versus 17% on 177Lu‑PSMA‑617 alone, signaling a […]
The ongoing phase Ib/II trial investigating the combination of AMO959, Pluvicto (lutetium-177 vipivotide tetraxetan, also known as AAA617 or 177Lu-PSMA-617), and androgen receptor pathway inhibitors (ARPIs) in metastatic castration-resistant prostate cancer (mCRPC) explores a novel approach targeting disease through multiple pathways. AMO959 is a direct activator of AMPK, a key metabolic regulator that can disrupt […]
To join the phase 2 POSTPONE trial investigating pacritinib for advanced prostate cancer, patients must have metastases that are strongly positive for STAT5 activation—specifically, a recent tumor biopsy must show detectable nuclear STAT5 in more than 5% of cancer cells. This trial is built upon robust laboratory and clinical findings showing that the JAK2-STAT5 pathway […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy